Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep:200:193-202.
doi: 10.1016/j.ygyno.2025.08.007.

Embracing and implementing the WHO cervical cancer elimination campaign goals: A consensus statement by SGO, ACOG, ASCCP, ASTRO, and ABS on minimum quality care standards for cervical cancer patients in the U.S

Nancy Zhou  1 , Anna L Beavis  2 , Lilie L Lin  3 , Shane S Neibart  4 , Junzo Chino  5 , Jennifer Young Pierce  6 , Roisin E O'Cearbhaill  7 , Summer B Dewdney  8 , Huma Farid  9 , Lee-May Chen  10 , Levi S Downs Jr  11 , Alexander B Olawaiye  12 , Teresa K L Boitano  13 , Mark H Einstein  14 , Deanna Teoh  15 , Charles A Leath 3rd  16
Affiliations

Embracing and implementing the WHO cervical cancer elimination campaign goals: A consensus statement by SGO, ACOG, ASCCP, ASTRO, and ABS on minimum quality care standards for cervical cancer patients in the U.S

Nancy Zhou et al. Gynecol Oncol. 2025 Sep.

Abstract

The World Health Organization (WHO) has clearly published the necessary metrics for elimination of cervical cancer as a public health problem, which includes adequate treatment of both cervical cancer and its precursors for at least 90 % of affected individuals. To improve cervical cancer outcomes, universal access to the best surgical procedures, radiation therapy including brachytherapy, and systemic therapy as well as palliative care and end-of-life care is paramount. Although implementation at the state and regional levels can be impactful, providing uniform high-quality treatment throughout the United States is needed to achieve the WHO goal. This manuscript defines broadly acceptable minimum standards of care which need to be funded with closed loopholes for access and payment to achieve eradication of cervical cancer as a public health problem.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest Dr. Beavis reports grants to her institution from the American Cancer Society and Pfizer Global Medical and consulting fees from Ethicon. Dr. Chino reports consulting fees from Stryker, honoraria from the GOG Foundation, participation on a Data Safety Monitoring Board for Kortuc Pharmaceuticals, and participation as a Board member of the American Brachytherapy Society. Dr. Olawaiye reports participation on an Advisory Board for GSK, AstraZeneca, Merck, Genentech, Eisai, and Daiichi-Sanckyo. Dr. Chen reports royalties from UpToDate for endometrial and ovarian cancer topics and unpaid leadership roles as the Society of Gynecologic Oncology liaison to the American College of Obstetricians and Gynecologists Board of Directors and a National Cancer Institute PDQ Cancer Genetics Board member. Dr. Einstein has advised or participated in educational speaking activities but does not receive an honorarium from any companies. In specific cases, his employer has received payment for his time spent for these activities from Merck, Douglas Pharmaceuticals Ltd., Becton-Dickenson, and PDS Biotechnologies. If travel required for meetings with industry, the company pays for Dr. Einstein's travel expenses. Rutgers has received grant funding for research-related costs of clinical trials that he has been the overall or local PI within the past 12 months from Inovio, Merck Sharp and Dohme Corp., Iovance, Papivax and VBL Therapeutics. Dr. Lin reports grants to her institution from the National Cancer Institute, AstraZeneca, Pfizer, and Varian, and participation on the Trevarx Scientific Advisory Board. Dr. Leath reports grants to his institution from the National Institutes of Health (UG1 CA233330 and P50 CA098252), Seattle Genetics, and Agenus, and participation on an Advisory Board for Seattle Genetics and Merck. Dr. Neibart reports grants from NCATS UL1TR003017, RSNA RMS2126, and MGB Center of Expertise, consulting fees from Hibiscus BioVentures and Radiant BioConsulting. Dr. O'Cearbhaill reports consulting fees from Tesaro/GSK, Regeneron, R-PHARM, Seattle Genetics, Miltenyi, Immunogen, Fresenius Kabi, Gynecologic Oncology Foundation, Bayer, Curio and 2seventybio, participation as a non-compensated steering committee member for the PRIMA, Moonstone (Tesaro/GSK) and DUO-O (AstraZeneca) studies and a non-compensated advisor for Carina Biotech, other from Hitech Health, and institutional funding for clinical research from Bayer/Celgene/Juno, Tesaro/GSK, Merck, Ludwig Cancer Institute, Abbvie/StemCentrx, Regeneron, TCR2 Therapeutics, Atara Biotherapeutics, MarkerTherapeutics, Syndax Pharmaceuticals, Genmab/Seagen Therapeutics, Sellas Therapeutics, Genentech, Kite Pharma, Acrivon, Lyell Immunopharma, and Gynecologic Oncology Foundation. Dr. Downs reports a leadership role as President of the American Society of Colposcopy and Cervical Pathology. Dr. Teoh reports a grant from the Department of Defense W81XWH-21-1-0347, and institutional funding for clinical research from Tesaro/GSK, Moderna, and Jounce Therapeutics, and particiaption in an Advisory Board for Asieris. She reports non-compensated Scientific Advisory Board membership on the Fanconi Cancer Foundation. Drs. Zhou, Young Pierce, Dewdney, and Farid have nothing to disclose.

Publication types